Multiple Vertebral Fractures Following Discontinuation of Prolia Treatment

Learn More

Green arrow pointing down

Multiple vertebral fractures may occur following discontinuation of treatment with Prolia, particularly in patients with a history of vertebral fracture.1

Advise patients not to interrupt Prolia therapy without their physician’s advice.1

Evaluate the individual benefit/risk before discontinuing treatment with Prolia.1

If Prolia treatment is discontinued, consider transitioning to an alternative antiresorptive therapy. 1

Additional Resources

ProVital Icon
ProVital

Find out more about the ProVital Patient Support Program

Provital patient
support programArrow Image
Administration Icon
Administration

Learn more about Prolia storage and administration

Storage and InjectionArrow Image
References
1. Amgen Canada Inc. Prolia® (denosumab injection) Product Monograph. November 24, 2023.
Safety logo

You are now leaving the Prolia.ca website.

The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk.

Do you want to link to our other external sites and leave Prolia.ca?

You are now leaving the Prolia.ca website. Please note that the information you are about to view may not comply with Canadian regulatory requirements. Marketing authorizations and availability of products may differ between Canada and other countries.

Proceed

Do you want to link to another Amgen Canada site?

Yes, leave Prolia.ca  

You are now leaving the Prolia.ca website. Please note that these links are being provided as a convenience and for informational purposes only.